Manager × security

JOHNSON & JOHNSON PTGX holdings history

Who else holds this security? →

PROTAGONIST THERAPEUTICS INC · CUSIP 74366E102 · CIK 200406

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, JOHNSON & JOHNSON reported 2.45M PTGX (shares), valued at $300.22M, or 37.59% of its reported non-derivative portfolio. Filed 2026-08-06.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
37.59%
Shares
2.45M
2,449,183
Reported value
$300.22M
USD

Shares unchanged; reported value increased 16.30%, and weight changed -1.98 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202637.59%2,449,183SEC filing ↗Filed Aug 6, 2026
Q1 202639.57%2,449,183SEC filing ↗Filed May 13, 2026
Q4 202538.54%2,449,183SEC filing ↗Filed Mar 18, 2026Amended
Q3 202532.29%2,449,183SEC filing ↗Filed Mar 18, 2026Amended
Q2 202540.83%2,449,183SEC filing ↗Filed Jul 22, 2025
Q1 202534.65%2,449,183SEC filing ↗Filed May 7, 2025
Q4 202424.48%2,449,183SEC filing ↗Filed Feb 13, 2025
Q3 202425.79%2,449,183SEC filing ↗Filed Nov 13, 2024
Q2 202421.18%2,449,183SEC filing ↗Filed Aug 9, 2024
Q1 20241.61%2,449,183SEC filing ↗Filed May 10, 2024
Q4 20231.28%2,449,183SEC filing ↗Filed Feb 14, 2024
Q3 202315.05%2,449,183SEC filing ↗Filed Nov 9, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202315.05%2,449,183$40.85MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 9, 2023
Q4 20231.28%2,449,183$56.16MShares unchanged; reported value increased 37.47%, and weight changed -13.77 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20241.61%2,449,183$70.85MShares unchanged; reported value increased 26.17%, and weight changed +0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 10, 2024
Q2 202421.18%2,449,183$84.86MShares unchanged; reported value increased 19.77%, and weight changed +19.57 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 9, 2024
Q3 202425.79%2,449,183$110.21MShares unchanged; reported value increased 29.87%, and weight changed +4.61 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 202424.48%2,449,183$94.54MShares unchanged; reported value decreased 14.22%, and weight changed -1.31 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2025
Q1 202534.65%2,449,183$118.44MShares unchanged; reported value increased 25.28%, and weight changed +10.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 7, 2025
Q2 202540.83%2,449,183$136.40MShares unchanged; reported value increased 15.16%, and weight changed +6.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Jul 22, 2025
Q3 202532.29%2,449,183$162.70MShares unchanged; reported value increased 19.29%, and weight changed -8.54 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Mar 18, 2026
Q4 202538.54%2,449,183$213.91MShares unchanged; reported value increased 31.48%, and weight changed +6.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Mar 18, 2026
Q1 202639.57%2,449,183$258.14MShares unchanged; reported value increased 20.68%, and weight changed +1.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2026
Q2 202637.59%2,449,183$300.22MShares unchanged; reported value increased 16.30%, and weight changed -1.98 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 6, 2026
JOHNSON & JOHNSON · PROTAGONIST THERAPEUTICS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"200406","quarter":"2026Q2","cusip":"74366E102"}

get_institutional_manager_history
{"cik":"200406","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.